skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Show only
Refined by: subject: Coronaviruses remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Material Type:
Article
Add to My Research

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Nature (London), 2021-08, Vol.596 (7871), p.276-280 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;Copyright Nature Publishing Group Aug 12, 2021 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03777-9 ;PMID: 34237773

Full text available

2
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Material Type:
Article
Add to My Research

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Nature Medicine, 2022-06, Vol.28 (6), p.1297-1302 [Peer Reviewed Journal]

2022. The Author(s), under exclusive licence to Springer Nature America, Inc. ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1078-8956 ;EISSN: 1546-170X ;EISSN: 1744-7933 ;DOI: 10.1038/s41591-022-01792-5 ;PMID: 35322239

Full text available

3
Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination
Material Type:
Article
Add to My Research

Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination

Viruses, 2022-07, Vol.14 (7), p.1491 [Peer Reviewed Journal]

COPYRIGHT 2022 MDPI AG ;2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;2022 by the authors. 2022 ;ISSN: 1999-4915 ;EISSN: 1999-4915 ;DOI: 10.3390/v14071491 ;PMID: 35891471

Full text available

4
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Material Type:
Article
Add to My Research

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

Science Translational Medicine, 2020-09, Vol.12 (559) [Peer Reviewed Journal]

2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;ISSN: 1946-6234 ;EISSN: 1946-6242 ;DOI: 10.1126/scitranslmed.abc3103 ;PMID: 32817357

Digital Resources/Online E-Resources

5
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases
Material Type:
Article
Add to My Research

Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases

Annals of the rheumatic diseases, 2022-05, Vol.81 (5), p.720-728 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage ;Distributed under a Creative Commons Attribution 4.0 International License ;Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. 2022 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-221508 ;PMID: 35022159

Full text available

6
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Material Type:
Article
Add to My Research

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

Proceedings of the National Academy of Sciences - PNAS, 2022-05, Vol.119 (20), p.e2120976119-e2120976119 [Peer Reviewed Journal]

Copyright National Academy of Sciences May 17, 2022 ;Attribution ;Copyright © 2022 the Author(s). Published by PNAS. 2022 ;ISSN: 0027-8424 ;EISSN: 1091-6490 ;DOI: 10.1073/pnas.2120976119 ;PMID: 35549549

Full text available

7
Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection
Material Type:
Article
Add to My Research

Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection

The Journal of infectious diseases, 2021-11, Vol.224 (9), p.1489-1499 [Peer Reviewed Journal]

The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. 2021 ;The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. ;Attribution - NonCommercial - NoDerivatives ;ISSN: 0022-1899 ;EISSN: 1537-6613 ;DOI: 10.1093/infdis/jiab375 ;PMID: 34282461

Full text available

8
Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual
Material Type:
Article
Add to My Research

Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual

Open forum infectious diseases, 2021-08, Vol.8 (8), p.ofab369-ofab369 [Peer Reviewed Journal]

The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2021 ;COPYRIGHT 2021 Oxford University Press ;Attribution - NonCommercial - NoDerivatives ;ISSN: 2328-8957 ;EISSN: 2328-8957 ;DOI: 10.1093/ofid/ofab369 ;PMID: 34377731

Full text available

9
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
Material Type:
Article
Add to My Research

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

BioRxiv, 2021-12

2021. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1101/2021.12.14.472630

Digital Resources/Online E-Resources

10
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Material Type:
Article
Add to My Research

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

bioRxiv, 2021-10

2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1101/2021.09.28.462234

Digital Resources/Online E-Resources

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (8)

Searching Remote Databases, Please Wait